$Stock*Shop*Charts*News*Option$

[kidstockster101]

POSC (.10) Positron Corporation and Disease Management, LLC Sign Agreement to Co-Develop a Coronary Artery Disease Reversal and Prevention Software Program and Total Disease Management Solution
Tuesday, June 24 2008 12:29 PM, EST

Business Wire    "US Press Releases "
HOUSTON --(BUSINESS WIRE)--
Positron Corporation (OTC:POSC) and Disease Management, LLC have announced an agreement to co-develop a coronary artery disease prevention and reversal software program and total disease management solution.
The product will include a heart disease pre-test risk calculator, a Coronary Disease Reversal and Prevention practice management program, a web-based, patient centric, disease reversal and life style modification program, an interpreting and referring physician portal, as well as a cost efficacy and patient outcomes tracker.
Positron Corporation's President Joseph G. Oliverio stated, "The development of our heart disease management solution will help us reach beyond our current molecular imaging targeted business to offer a product to payers, self insured corporations, multi-specialty groups, cardiology groups, hospitals and finally direct to the consumer."
Oliverio also adds that "This is an important step in the growth of our business and the impact on the industry that Positron has been positioning for over the past 2 years. The product introduction will address a first-to-market opportunity in the Coronary Disease Reversal and Prevention sector which strengthens Positron's core products that are focused on providing accurate, cost effective imaging and disease management solutions. One of our many goals is to offer even the smallest community hospitals the same level of quality of our most experienced users."
About Positron Corporation
Positron Corporation is a growing healthcare company offering cardiac molecular imaging solutions that will transform the delivery of healthcare through radiopharmaceutical development, advancing imaging technology and by introducing unique disease management applications into the market. Positron Corporation designs, manufactures and sells SPECT, PET and automated dose delivery devices in to the Nuclear Medicine market. Additional information may be found at http://www.positron.com/.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Positron Corporation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing and other uncertainties described in the "Management's Discussion and Analysis" section of the Company's Form 10-KSB and other reports and filings with the Securities and Exchange Commission .
For any additional information contact Positron's President, Joe Oliverio at [phone].
Source: Positron Corporation